MCAM and melanoma: In particular, treating cells with antibodies against MCAM reduced proliferation for approximately 60%, migration for 75%, and tube formation in human umbilical vein endothelial cells (HUVEC), and invasion in melanoma and osteosarcoma cells, while the proliferation of melanoma, hepatocarcinoma, osteosarcoma, ovary, and cervix tumor cells was not affected [21,22,23,24].